- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA: Drug combo may lead to serotonin syndrome
Taking triptans to fight off a migraine together with either a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) may lead to the development of serotonin syndrome, according to a new FDA warning. The three types of medications all raise the level of serotonin in the body and can lead to symptoms such as restlessness, loss of coordination, tachycardia, blood pressure changes, increased body temperature, nausea, vomiting, and diarrhea.
FDA: Drug combo may lead to serotonin syndrome
Taking triptans to fight off a migraine together with either a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake inhibitor (SNRI) may lead to the development of serotonin syndrome, according to a new FDA warning. The three types of medications all raise the level of serotonin in the body and can lead to symptoms such as restlessness, loss of coordination, tachycardia, blood pressure changes, increased body temperature, nausea, vomiting, and diarrhea. To avoid the potentially life-threatening situation, the agency warned prescribers to weigh the potential risk of serotonin syndrome against the benefit of using the above combination and to discuss the possibility of developing the syndrome with patients if a triptan and an SSRI or SNRI are to be used together. The FDA also recommended monitoring patients closely during treatment if these drugs are prescribed together and has requested that manufacturers update their prescribing information to reflect the possibility of serotonin syndrome.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
Stress Ulcer Prophylaxis May Not Prevent Gastrointestinal Bleeding in Neonates
December 4th 2023According to a poster presented at ASHP Midyear 2023, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.
Instagram Could Serve as Educational Platform for New FDA Drug Approvals
December 4th 2023An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
